Saudi Central Bank Has $2.79 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Saudi Central Bank increased its Alnylam Pharmaceuticals stake by 90.4% in the second quarter, reaching 9,284 shares valued at approximately $2.795 million. Institutional investors collectively own 92.97% of the company.
• Wall Street maintains a positive outlook, with a consensus rating of “Moderate Buy” from 25 analysts and an average price target of $386.14, despite several recent target-price cuts.
• Alnylam reported quarterly earnings of $1.84 per share, exceeding estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion, slightly below analyst expectations.

Saudi Central Bank increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 90.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,284 shares of the biopharmaceutical company's stock after buying an additional 4,408 shares during the period. Saudi Central Bank's holdings in Alnylam Pharmaceuticals were worth $2,795,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ALNY. AlphaGrep UK Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $489,000. Raiffeisen Bank International AG grew its holdings in Alnylam Pharmaceuticals by 29.7% in the 2nd quarter. Raiffeisen Bank International AG now owns 13,510 shares of the biopharmaceutical company's stock valued at $3,965,000 after buying an additional 3,097 shares during the last quarter. denkapparat Operations GmbH increased its position in Alnylam Pharmaceuticals by 151.4% in the 2nd quarter. denkapparat Operations GmbH now owns 2,594 shares of the biopharmaceutical company's stock worth $781,000 after buying an additional 1,562 shares during the period. Concurrent Investment Advisors LLC increased its position in Alnylam Pharmaceuticals by 695.9% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 7,521 shares of the biopharmaceutical company's stock worth $2,264,000 after buying an additional 6,576 shares during the period. Finally, NEOS Investment Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 13.6% during the second quarter. NEOS Investment Management LLC now owns 78,274 shares of the biopharmaceutical company's stock worth $23,563,000 after buying an additional 9,401 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ALNY shares. JPMorgan Chase & Co. lowered their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Needham & Company LLC cut their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Sanford C. Bernstein reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Barclays decreased their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating on the stock in a research report on Monday, August 3rd. Finally, Oppenheimer cut their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $386.14.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $266.11 on Tuesday. The firm has a market cap of $35.61 billion, a PE ratio of 49.46 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The company's 50-day moving average price is $258.70 and its two-hundred day moving average price is $290.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the business posted ($0.51) earnings per share. The company's revenue was up 66.9% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.